Search Bar & Filters
Found 9 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating changes in bone mineral density in premenopausal women with heavy menstrual bleeding caused by uterine fibroids or moderate-to-severe pain from endometriosis. This Phase 3B, open-label study looks at the effects of continuous treatment with a relugolix combination tablet for up to 48 months 4 years, followed by a 1-year period to monitor bone health after stopping treatment. Participants will take a daily oral relugolix combination tablet containing relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg for 4 years. Bone mineral density will be measured every 6 months using dual-energy X-ray absorptiometry DXA. Some women who have completed a previous related study may join to complete 3 years of treatment. After treatment ends, bone density will be checked again at 6 months and 12 months during the follow-up year. Women in the study will have regular visits for bone density scans and health assessments, including physical and gynecological exams, lab tests, and vital signs. Researchers will track changes in bone density at the spine, hip, and femoral neck throughout treatment and follow-up. They will also monitor for any fractures or adverse events during the 4 years of treatment and the 1-year post-treatment period. Total participation can last up to 5 years including the follow-up.
Actively Recruiting
Researchers are evaluating the safety and preliminary effects of a single intradiscal injection of BRTX-100 in adults with chronic lumbar disc disease, a condition causing back and leg pain due to degeneration of spinal discs confirmed by imaging and clinical evaluation. This is a phase 2, double-blind, randomized study with controlled and blinded assessments to compare BRTX-100 against a sham procedure treatment. Participants will be randomly assigned to receive either BRTX-100, which contains specially cultured stem cells from their own bone marrow combined with platelet lysate, or a control group receiving a sham procedure with saline. Those in the treatment group will undergo bone marrow collection to prepare the BRTX-100 injection, while the control group will have bone marrow and blood collected but will not receive the active injection. The study includes a Safety Run-In phase with close monitoring of the first four treated participants before continuing the randomized phase. Follow-up visits will occur at weeks 2, 12, 26, 52, and 104 or early termination. During the study, participants will be monitored through physical exams, lab tests, and safety assessments to track any adverse effects and evaluate treatment impact. Primary safety measures will be assessed from baseline through week 104, and efficacy will be evaluated through week 52. The study aims to gather detailed information on safety and initial effectiveness while participants continue regular evaluations over two years, with careful oversight by medical monitors and a data safety board.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the ReGelTec HYDRAFIL System in adults with axial chronic low back pain caused by degenerative disc disease DDD. This pivotal, multi-center, randomized controlled trial focuses on patients who continue to experience severe back pain and dysfunction after at least six months of conservative care. The study includes participants aged 22 to 85 years with symptomatic lumbar discs confirmed by imaging and discography. Participants are assigned to one of two groups the treatment arm receives the ReGelTec HYDRAFIL System hydrogel spinal implant combined with continued non-surgical conservative care, while the control arm receives conservative care plus a sham procedure involving needle advancement without muscle contact. After 24 months, eligible control participants may crossover to receive the treatment. The study monitors outcomes over at least 12 months and includes follow-up assessments. During the trial, participants undergo various evaluations including imaging MRI, discography, clinical assessments, and symptom monitoring. Researchers measure clinical success through a composite endpoint at 12 months. Participants are expected to adhere to follow-up schedules and complete questionnaires. Safety and effectiveness are continuously assessed throughout the study period, which extends up to the study completion date in late 2028.
Actively Recruiting
Healthy Volunteer
Researchers are establishing the Integrated Cancer Repository for Cancer Research iCaRe2 as a multi-institutional resource to collect and manage standardized, multi-dimensional, and longitudinal data and biospecimens from adult cancer patients, individuals at high risk, and normal controls. This resource covers a wide geographical area including small and rural hospitals and cancer centers. The goal is to advance comprehensive studies on cancer risk factors and enable development of new strategies for cancer prevention, screening, early detection, and personalized treatment. The iCaRe2 resource collects data and biospecimens such as tumor samples, germline DNA, serum, urine, and plasma from participants across multiple cancer registries covering various cancer types. It operates as a web-based, HIPAA-compliant platform allowing centers with different expertise to contribute and collaborate. This repository supports cohort and population studies by providing a secure, standardized, and interoperable system for cancer-related data collection and sharing. Participants include adult patients with cancer, individuals at risk, and normal controls who can provide informed consent. Data collected includes clinical information, biospecimens, and longitudinal follow-up. The study measures include the development and implementation of the web-based registry and banking of biological materials for future research. Participation involves consent and data contribution, with monitoring and data validation ensuring quality. The repository enables ongoing research collaborations to study cancer biology, genetics, epidemiology, and patient care.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are evaluating LUM-201 as a treatment for Pediatric Growth Hormone Deficiency PGHD in children who have not previously received treatment. This multinational Phase 3 clinical trial aims to assess the safety and effectiveness of daily oral LUM-201 and to validate a predictive marker to identify children most likely to respond to this therapy. The study compares daily oral doses of LUM-201 at 1.6 mgkg to a matched placebo, in a randomized, double-blind manner. Participants are prepubertal children aged 3 to 11 years, treated over a 12-month period. The trial measures growth outcomes while monitoring safety and response to the medication. Participants undergo regular assessments including growth measurements and hormone evaluations over the year-long treatment. The primary outcome is annualized height velocity after 12 months of treatment with LUM-201 compared to placebo. Safety is monitored throughout the trial, with follow-up continuing until study completion in early 2028.
Actively Recruiting
This research aims to gather real-world data on the outcomes of Boston Scientific neurostimulation systems used for pain management in everyday clinical practice. It focuses on evaluating the long-term effectiveness, economic value, and technical performance of these commercially approved neurostimulation devices when used according to their instructions. Participants will undergo a trial period with a Boston Scientific neurostimulation system for pain. Those who experience positive results from the trial may then receive a permanent implant of the neurostimulation system. The therapy will be personalized based on the investigators judgment and routine site care, following the studys inclusion and exclusion criteria. During the study, participants will be monitored as they receive neurostimulation therapy in real-world settings. Researchers will collect information on treatment outcomes and device performance over time. The study spans from 2012 to 2035, allowing for long-term observation of participants using these neurostimulation systems for pain relief.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety and effectiveness of the Cytrellis Micro-Coring Device for treating moderate to severe wrinkles on the face, specifically focusing on the cheeks and neck areas. This study involves up to 35 adults aged 40 to 70 years with Fitzpatrick Skin Types I to IV. The goal is to improve skin appearance by reducing wrinkle severity using this novel device. Participants will undergo one treatment session using the micro-coring device, which removes small sections of skin on the face and neck. Following this treatment, participants will be monitored closely for 90 days to assess changes and any side effects. The study includes various methods to evaluate wrinkle improvement, such as the Lemperle Wrinkle Severity Scale and other aesthetic improvement scales. During the study, participants will have scheduled assessments to measure wrinkle severity and satisfaction with treatment results. Safety monitoring will include recording any adverse events immediately after treatment and at several follow-up visits up to 90 days later. Participants will also complete a diary for two weeks post-treatment to track any side effects. The total involvement period for each participant is approximately three months.
Actively Recruiting
Healthy Volunteer
This research aims to assess the presence and severity of coronary artery disease CAD in retired NFL players. It is a post-market, multi-center observational study focusing on former NFL athletes who made either a practice squad or an active roster. The study will include around 300 participants from approximately 20 sites across the United States to better understand heart disease risks in this unique population. Participants will undergo Coronary Computed Tomography Angiography CCTA, a non-invasive imaging test that uses X-rays to produce detailed 3D images of the heart and its blood vessels, especially the coronary arteries. This diagnostic procedure helps identify coronary artery disease and plaque burden in the arteries. The study involves collecting and analyzing this imaging data to evaluate cardiac risk among NFL alumni. During the study, researchers will monitor participants CCTA results within 24 hours to identify those with CAD, physiologically significant CAD, and high coronary plaque burden. The data collection focuses on these heart health indicators, without any treatment intervention. Participation may involve completing the CCTA imaging and providing relevant health information, with the study expected to conclude by the end of 2026.